Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
We encourage you to schedule a consultation to discuss whether peptide therapy might be a beneficial addition to your personalized treatment plan
The only retrospective human study included 12 patients who received intra-articular BPC-157 for chronic knee pain, of whom 7 reported symptom improvement lasting more than 6 months
It was crazy
But in practice, and especially with regard to synthetic and recombinant peptide forms, there are some considerable potential safety concerns: Immunogenicity Most notably, per a 2020 assessment on therapeutic peptide safety, synthetic and recombinant peptides pose the risk of immunogenicity the ability of a substance to provoke an immune response.15 An immunogenicity-inducing peptide, when introduced to the body, would cause the bodys immune system to perceive the peptide not as a medication but as a threat
PubMed laboratory research record [PMID: 41709697] PubMed record related to this compound for laboratory literature review
US$ 21.46
US$ 26.55
US$ 21.76
US$ 21.75
